ATAI Life Sciences NV (9VC) — Net Asset Quality Index
ATAI Life Sciences NV (9VC) has a Net Asset Quality Index of 66.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €239.82 Million minus total liabilities of €79.91 Million yields net assets of €159.91 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of ATAI Life Sciences NV to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
ATAI Life Sciences NV Net Asset Quality Index Over Time (2019–2024)
This chart shows how ATAI Life Sciences NV's Net Asset Quality Index has evolved across 6 annual periods from 2019 to 2024. As of September 2025, the index stands at 66.7%, representing net assets of €159.91 Million against total assets of €239.82 Million EUR. See 9VC net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for ATAI Life Sciences NV (2019–2024)
The table below presents the year-by-year Net Asset Quality Index for ATAI Life Sciences NV from 2019 to 2024, covering 6 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 9VC company net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 73.1% | €116.55 Million | €159.39 Million | €42.83 Million | ▼ -10.1 pp |
| 2023 | 83.2% | €244.32 Million | €293.48 Million | €49.16 Million | ▼ -3.8 pp |
| 2022 | 87.0% | €265.77 Million | €305.44 Million | €39.67 Million | ▼ -6.2 pp |
| 2021 | 93.2% | €385.96 Million | €414.17 Million | €28.21 Million | ▲ +7.7 pp |
| 2020 | 85.5% | €95.37 Million | €111.55 Million | €16.18 Million | ▼ -10.5 pp |
| 2019 | 96.0% | €59.64 Million | €62.12 Million | €2.48 Million | — |